AAPL 184.35 1.1134% MSFT 411.6876 2.364% GOOG 145.3444 1.0459% GOOGL 144.175 1.14% AMZN 174.33 3.4047% NVDA 784.65 16.2927% META 486.18 3.878% TSLA 197.565 1.435% TSM 129.25 3.1195% LLY 769.655 3.1834% V 283.785 2.5383% AVGO 1304.8 6.3017% JPM 183.325 1.3405% UNH 525.425 0.6619% NVO 124.57 3.01% WMT 175.35 0.9499% LVMUY 182.36 1.7066% XOM 104.775 -0.0715% LVMHF 909.7617 1.9427% MA 471.85 2.7884%

Actinium Pharmaceuticals Inc

Healthcare US ATNM

6.76USD
0.10(1.50%)

Last update at 2024-02-22T20:52:00Z

Day Range

6.526.98
LowHigh

52 Week Range

4.0014.70
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -33.01700M -24.77400M -22.21500M -21.89905M -23.65396M
Minority interest - - - - -
Net income -31.93000M -24.58400M -22.03700M -21.72666M -23.65396M
Selling general administrative 12.00M 8.08M 6.31M 5.52M 6.73M
Selling and marketing expenses - - - - -
Gross profit 1.03M 1.14M - - 0.00000M
Reconciled depreciation 0.70M 0.52M 0.45M 0.42M 0.05M
Ebit -34.10400M -24.96400M -22.39300M -22.07145M -23.82732M
Ebitda -33.40500M -24.44000M -21.94600M -21.65136M -23.77660M
Depreciation and amortization 0.70M 0.52M 0.45M 0.42M 0.05M
Non operating income net other - - - - -
Operating income -34.10400M -24.96400M -22.39300M -22.07145M -23.82732M
Other operating expenses 35.13M 26.11M 22.39M 22.07M 23.83M
Interest expense -1.08700M 0.19M 0.00000M 0.00000M 0.17M
Tax provision - - - - -
Interest income 1.09M 0.19M 0.18M 0.17M 0.17M
Net interest income 1.09M 0.19M 0.18M 0.17M 0.17M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -1.08700M -0.19000M -0.17800M -0.17239M 0.17M
Total revenue 1.03M 1.14M 0.00000M 0.00000M 0.00000M
Total operating expenses 35.13M 26.11M 22.39M 22.07M 23.83M
Cost of revenue - - - - 0.00000M
Total other income expense net 1.09M 0.19M 0.18M 0.17M 0.17M
Discontinued operations - - - - -
Net income from continuing ops -33.01700M -24.77400M -22.21500M -21.89905M -23.65396M
Net income applicable to common shares -33.01700M -24.77400M -22.21600M -21.90032M -23.65396M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 114.19M 80.39M 66.40M 11.67M 14.89M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 2.03M 1.92M 1.36M 0.83M 0.66M
Total liab 47.71M 6.84M 5.08M 6.03M 6.08M
Total stockholder equity 66.48M 73.55M 61.32M 5.64M 8.81M
Deferred long term liab - - - - -
Other current liab -24.87000M 6.53M 4.34M 4.60M 6.06M
Common stock 0.03M 0.02M 0.02M 0.16M 0.12M
Capital stock 0.03M 0.02M 0.02M 0.16M 0.12M
Retained earnings -288.76500M -255.74800M -230.97400M -208.75756M -186.85724M
Other liab 35.00M - - - -
Good will - - - - -
Other assets 0.30M - 1.16M 0.44M 0.44M
Cash 108.91M 77.83M 63.56M 9.25M 13.67M
Cash and equivalents - - - - -
Total current liabilities 10.63M 6.84M 4.77M 5.34M 6.06M
Current deferred revenue 35.00M - -4.34000M - -6.06324M
Net debt -106.32900M -77.51900M -62.82200M -7.82571M -13.41071M
Short term debt 0.50M 0.31M 0.43M 0.75M 0.25M
Short long term debt - - - 0.38M 0.25M
Short long term debt total 2.58M 0.31M 0.74M 1.43M 0.26M
Other stockholder equity 355.22M 329.27M 292.27M 214.24M 195.82M
Property plant equipment 2.95M 0.64M 1.03M 1.14M 0.12M
Total current assets 110.94M 79.75M 64.92M 10.09M 14.33M
Long term investments - - - - 0.05M
Net tangible assets 66.48M 73.55M 61.32M 5.64M 8.81M
Short term investments - - - - -
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 10.13M 5.54M 4.34M 4.60M 5.81M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - -0.23742M -0.26638M
Additional paid in capital - - - - -
Common stock total equity - 0.02M 0.02M 0.16M 0.12M
Preferred stock total equity - - - - -
Retained earnings total equity - -255.74800M -230.97400M -208.75756M -186.85724M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.30M 0.06M 0.44M 0.44M 0.39M
Deferred long term asset charges - - - - -
Non current assets total 3.25M 0.64M 1.47M 1.58M 0.56M
Capital lease obligations 2.58M 0.31M 0.74M 1.05M 0.01M
Long term debt total - - - 0.15M 0.01M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.36600M -0.13300M -0.25300M -0.06389M -0.09609M
Change to liabilities 38.60M 1.20M -0.25700M -1.25574M 1.13M
Total cashflows from investing activities -0.36600M -0.13300M -0.25300M -0.06389M -0.09609M
Net borrowings -0.04900M -0.08500M -0.46000M -0.24924M 0.02M
Total cash from financing activities 23.11M 35.22M 76.18M 17.11M 16.98M
Change to operating activities -0.43000M 0.49M -0.84600M -0.02145M 0.10M
Net income -33.01700M -24.77400M -22.21500M -21.89905M -23.65396M
Change in cash 31.39M 14.22M 54.31M -4.41126M -3.68606M
Begin period cash flow 78.22M 64.00M 9.69M 14.10M 17.79M
End period cash flow 109.61M 78.22M 64.00M 9.69M 14.10M
Total cash from operating activities 8.64M -20.86600M -21.61700M -21.46145M -20.57106M
Issuance of capital stock 23.16M 35.30M 76.59M 15.93M 16.98M
Depreciation 0.70M 0.52M 0.45M 0.42M 0.05M
Other cashflows from investing activities - - - - -
Dividends paid - - -0.00100M -0.00127M -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - 35.31M 0.00100M 0.00127M 16.98M
Other cashflows from financing activities -0.36600M 0.00600M 0.05M 1.50M 0.00485M
Change to netincome 2.79M 1.69M 1.25M 1.29M 1.80M
Capital expenditures 0.37M 0.13M 0.25M 0.06M 0.10M
Change receivables - - - - -
Cash flows other operating - -0.50300M -0.84600M -0.02145M 0.10M
Exchange rate changes - - - - -
Cash and cash equivalents changes - 14.22M 54.31M -4.41126M -3.68606M
Change in working capital 38.17M 1.69M -1.10300M -1.27719M 1.23M
Stock based compensation 2.79M 1.69M 1.25M 1.29M 1.80M
Other non cash items - -11.06100M -56.51700M 2.25M 6.14M
Free cash flow 8.28M -20.99900M -21.87000M -21.52534M -20.66715M

Fundamentals

  • Previous Close 6.66
  • Market Cap157.63M
  • Volume116093
  • P/E Ratio-
  • Dividend Yield0.0%
  • EBITDA-52.60800M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM0.0
  • Gross Profit TTM 1.03M
  • Diluted EPS TTM-1.93

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ATNM
Actinium Pharmaceuticals Inc
0.10 1.50% 6.76 0.0 6.84 266.69 2.92 1060.92 -0.8962
NVO
Novo Nordisk A/S
3.64 3.01% 124.57 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S
5.12 4.29% 124.40 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
7.83 1.87% 427.46 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd
1.03 1.11% 93.74 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

Profile

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple targets in oncology and hematology, including CD45, CD33, HER3, and other. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company is based in New York, New York.

Actinium Pharmaceuticals Inc

275 Madison Avenue, New York, NY, United States, 10016

Key Executives

Name Title Year Born
Mr. Sandesh C. Seth M.B.A., M.S., MBA Chairman & CEO 1964
Mr. Steven O'Loughlin BS CFO & Corp. Sec. 1986
Dr. Paul Diamond Esq., Ph.D. VP of Patent & Legal Counsel NA
Dr. David Gould Sr. VP of Corp. Devel. & Corp. Affairs NA
Dr. Bernie Cunningham P.M.P., Ph.D. Exec. Director of Clinical Supply Chain & Logistics and CMC Project Management NA
Dr. Qing Liang VP & Head of Radiation Sciences NA
Dr. Robert N. Daly M.S., Ph.D. VP & Head of Clinical Operations NA
Dr. Mamata Gokhale VP & Global Head of Regulatory Affairs NA
Dr. Avinash Desai M.D. Chief Medical Officer NA
Dr. Arun Swaminathan Ph.D. Chief Bus. Officer NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).